PharmExec Blog

Gilead Buys CV Therapeutics (Update 1)

The morning’s other big M&A news comes out of the Bay Area biotech industry, where Gilead Sciences announced that it will purchase CV Therapeutics for $1.4 billion. The sudden move frees Palo Alto-based cardiovascular company CV Therapeutics from the hostile embrace of Astellas Pharma, ending a messy $1.1 billion takeover attempt. With the acquisition, Gilead, which has rocketed to glory with an arsenal of market-leading HIV drugs, extends its reach into the heart-disease realm, where many blockbusters-to-be from Pfizer, Merck, and other giants have recently come to grief.

Gilead, the Foster City, CA, powerhouse will pay cash for the deal.

In A conference call, Gilead CEO John Martin, COO John Mulligan, and R&D wizard Norbert Bischogberger had to deal with a fair amount of skepticism from industry analysts, who poked and prodded with questions about the deal, aiming to find its vulnerable spots. And there are several.

From CV Therapeutics, Gilead gets two marketed products: Ranexa, a $100 million seller in chronic angina; and Lexiscan, a $50 million drug for mycocardial perfusion imaging—plus a pipeline including two Phase III molecules for atrial-fibrillation molecule and heart failure.

Analysts asked whether Gilead was placing too big a bet on two hopes: that Ranexa, with a new label for first line treatment, will grab a major piece of the angio market; and that the platform will indeed deliver. The biotech is also banking on its own Phase III compound, darusentan, for persistent hypertension. In addition, CV Therapeutics sales force nicely expands Gilead’s access to cardio specialists. If everything works out as planned, the innovative specialty drugmaker could find itself leading in the blockbuster-making primary-care market. That would be a truly remarkable accomplishment.

Under tough questioning, the Gilead team stuck to their guns, proclaiming complete confidence in both their planned relaunch of Ranexa and the approval of darusentan in the competitive hypertension field, where other brave new molecules have failed.

Is it all a bridge too far, analysts wondered. Based on Gilead’s track record, maybe not. Martin reminded them that “we didn’t have to do this acquisition” (unlike some pharmas, hint, hint). But rather than sit on their cash pile, Gilead chose to roll the dice in a new game. That’s biotech talking.

Update 3/16/09: Astellas announced Monday morning that it would not engage in a bidding war with Gilead and terminated its $16 per share offer.

“Astellas also intends to withdraw a related lawsuit in the Delaware Chancery Court against CV Therapeutics and its directors,” the company stated in a release. “Astellas is a disciplined acquirer and does not see value for Astellas stockholders in CV Therapeutics at the price level ofthe sale announced on March 12.”

This entry was posted in Deals and tagged , , , , , , , . Bookmark the permalink. Post a comment or leave a trackback: Trackback URL.


  1. Posted March 14, 2009 at 5:01 pm | Permalink

    You guys in your release seemed assuring that the deal to buy CVTX will be fdinalized as disclosed. My analytical experience suggests that CVTX with its top quality drug stream is worth at least $3 more per share. C’mon guys cough it up. Charles Stevens

  2. Posted March 1, 2011 at 9:15 am | Permalink

    I loved as much as you’ll receive carried out right here. The sketch is attractive, your authored subject matter stylish. nonetheless, you command get bought an edginess over that you wish be delivering the following. unwell unquestionably come further formerly again as exactly the same nearly a lot often inside case you shield this hike.

  3. Posted July 23, 2011 at 7:16 pm | Permalink

    Howdy excellent post.
    Does someone use cheaper SMS message marketing services for shops+stores at California than They only cost nine dollars / 30 days which is not much, unfortunately my friend Jeremiah told me there is, unfortunately he couldn’t recall its name. l definitely start to get suspicion that he recalled wrongly. Please reply

Post a Comment

Your email is never published nor shared. Required fields are marked *


You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>

  • Categories

  • Meta